Transplant Surgery

Transplant surgery is the branch of surgery that removes a living organ or tissue from one body and connects it to another—or to a different place in the same body—so that it can take over a failing function.

10 frameworks, from 1902 to today · Surgery · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Transplant surgery is the branch of surgery that removes a living organ or tissue from one body and connects it to another—or to a different place in the same body—so that it can take over a failing function1. Its practitioners move kidneys, livers, hearts, lungs, pancreases, and increasingly hands and faces between people, and they must solve a problem no other surgeon faces: the recipient's immune system is built to destroy anything that is not its own. What is at stake is therefore double. Technically, the surgeon must sew vessels small enough that a few stitches too many can clot the graft; biologically, the patient must be persuaded, with drugs or with clever matching, to tolerate a foreign organ for years. Transplant surgery sits at the meeting point of operative craft, immunology, and public policy, and its history is the story of how each of those was brought under control.

Skin Grafts and the First Vision of Replacement

Long before organs could be moved, surgeons learned that tissue could be transplanted at all. Skin grafting for burns and wounds is ancient—the Indian surgeon Sushruta's compendium describes reconstructive flaps around the first millennium BCE—but the modern scientific question was posed in the eighteenth and nineteenth centuries, when experimenters moved skin, bone, and teeth between animals and observed that grafts from another individual usually withered while grafts from the same animal sometimes took. The Scottish surgeon John Hunter, working in London in the late 1700s, transplanted human teeth and animal tissues in experiments that were as much curiosity as therapy. By the early twentieth century the French surgeon Alexis Carrel had solved the technical bottleneck: working at the Rockefeller Institute in New York, he developed the triangulation method of vascular anastomosis—joining two blood vessels by stitching three equidistant stay sutures around the circumference and running the edges together between them—and with Charles Guthrie he transplanted kidneys, hearts, and limbs in dogs. Carrel's suturing technique, rewarded with the Nobel Prize in 1912, made it possible to reconnect an organ's blood supply at all. What it could not do was explain why the grafts failed weeks later.

The Immunology of Rejection

That explanation came from biology. In the 1940s the British zoologist Peter Medawar, studying burns in airmen during the Second World War, showed that skin grafted from one person to another was destroyed by an active immune response, not by poor technique—a "second-set" graft from the same donor was rejected faster than the first, the signature of immunological memory. Medawar and colleagues then demonstrated in mice and cattle that a graft could survive if the recipient had been exposed to the donor's tissue before its immune system matured; this acquired tolerance, published in 1953, established that rejection was a learned response that might be unlearned. The genetic basis was mapped at the same time: the histocompatibility antigens—surface proteins that the immune system uses to distinguish self from non-self—were traced in mice to a single region, later called the major histocompatibility complex, and in humans to the HLA system on chromosome 6. Tissue typing, the laboratory matching of donor and recipient HLA, grew from this work in the 1960s. The lesson practitioners drew was double-edged: better matching reduced rejection, but because the HLA genes are enormously variable, most patients would never find a perfect match, so matching alone could not solve the problem.

The First Successful Kidney Transplants

The surgical breakthrough came in Boston. On 23 December 1954, Joseph Murray and colleagues at the Peter Bent Brigham Hospital transplanted a kidney between identical twins—Ronald and Richard Herrick—and the organ functioned2. Because the twins were genetically identical, the operation sidestepped immunology entirely and proved that a transplanted kidney could sustain life12. Murray's team went on to attempt transplants between non-identical siblings and unrelated donors, using body irradiation to suppress the immune system; some grafts functioned for months or years, but infection and rejection took a heavy toll. The Brigham programme, together with Jean Hamburger's group in Paris and others in the late 1950s, established the template of the modern transplant unit: a surgical team, a tissue-typing laboratory, and a medical team managing immunosuppression. The first successful kidney transplant in the United Kingdom, at Edinburgh in 1960, followed the same model.

Chemical Immunosuppression

The decisive turn was pharmacological. In 1959 the American researchers Robert Schwartz and William Dameshek showed that the drug 6-mercaptopurine could suppress antibody production in rabbits, and the Burroughs Wellcome chemist Gertrude Elion and her colleague George Hitchings developed a related compound, azathioprine, that was less toxic. In 1963 the Boston surgeon Roy Calne, working with Elion and Hitchings, reported that azathioprine combined with steroids prolonged kidney graft survival in dogs, and the combination entered clinical use. The effect was transformative: one-year kidney graft survival, previously a gamble, climbed steadily through the 1960s. In 1972 Calne's team in Cambridge identified cyclosporine—a fungal metabolite first isolated by Sandoz scientists—as a powerful and more selective immunosuppressant, and its clinical introduction in the late 1970s and early 1980s, together with the steroid-sparing regimens built around it, pushed kidney and then heart and liver transplantation from experimental to routine. Later drugs—tacrolimus, mycophenolate, and antibody induction agents—refined the balance between preventing rejection and leaving the patient vulnerable to infection and cancer. The field's persistent problem, which remains open, is that all these drugs suppress immunity broadly rather than teaching the body to accept one particular organ.

Brain Death and the Deceased-Donor Framework

Organ transplantation needed donors, and donors needed a definition of death that did not require the heart to stop. In 1959 the French neurologists Pierre Mollaret and Maurice Goulon described coma dépassé, a state of irreversible unconsciousness with absent brainstem function, and through the 1960s intensive-care units learned to recognize it. In 1968 an ad hoc committee at Harvard Medical School published a report defining irreversible coma—"brain death"—by clinical criteria, and the same year the World Medical Association's Declaration of Sydney endorsed the concept. The timing was not accidental: the first heart transplant had been performed in December 1967, and the framework gave surgeons a legitimate source of organs from patients whose circulation was maintained artificially. Legal recognition followed country by country, and the "dead donor rule"—that vital organs may be taken only from patients declared dead—became the ethical foundation of deceased donation. Where brain-death law was absent or contested, as in Japan for decades, transplant programmes lagged.

Organ-Specific Programmes

With immunosuppression and donors in place, surgeons extended transplantation organ by organ. Thomas Starzl in Denver performed the first human liver transplant in 1963; early patients died, but survival improved through the late 1960s and 1970s, and cyclosporine made liver transplantation a standard therapy by the early 1980s. Christian Barnard's heart transplant in Cape Town in December 1967 captured the world's attention; after a period of poor results, Norman Shumway's group at Stanford sustained the programme through the 1970s and made heart transplantation reliable. Lung transplantation, first attempted in 1963 by James Hardy in Mississippi, became practical in the 1980s with the single-lung technique of Joel Cooper in Toronto and later bilateral procedures3. Pancreas and kidney-pancreas transplantation for diabetes, pioneered by Richard Lillehei and others in Minnesota in the late 1960s, followed the same arc4. Each organ brought its own surgical problems—biliary reconstruction in the liver, airway healing in the lung—and its own allocation debates.

Living Donation

Because deceased organs were scarce, surgeons turned to living donors. The first successful kidney transplant was itself a living-donor operation between twins, and through the 1960s and 1970s living related donation became routine, justified by better outcomes and the ability to plan the operation. The ethical framework that emerged—voluntary, informed, unpaid donation, with independent assessment of the donor—was codified in statements such as the 2008 Declaration of Istanbul, which condemned organ trafficking and transplant tourism. Laparoscopic donor nephrectomy, introduced in the late 1990s, reduced donor recovery time and helped living donation grow. In liver transplantation, living donation began in the late 1980s with paediatric cases in which a parent gave part of a liver, and adult-to-adult right-lobe donation followed; it remains concentrated in Asia, where deceased donation is limited. The unresolved tension is that living donation exposes a healthy person to surgical risk for another's benefit, and the field continues to debate how far it should be encouraged.

Allocation and Procurement Policy

As demand outran supply, transplant surgery became inseparable from policy. The United States created the Organ Procurement and Transplantation Network in 1984 and its scientific registry, and allocation rules evolved from local to national sharing, with scores such as the Model for End-Stage Liver Disease (MELD) introduced in 2002 to rank liver candidates by urgency rather than waiting time. Eurotransplant, founded in 1967, coordinates sharing across several European countries. Procurement itself became a specialty: organ procurement organizations manage donor identification, brain-death testing, and organ recovery, and the "preservation" of organs between donor and recipient—initially by cold storage in an ice-slush solution—was a constant constraint. The policy questions—geographic equity, urgency versus benefit, how to define a fair wait—remain live and are argued in the same journals that report surgical outcomes.

Machine Perfusion and the Return of the Organ as a Living Graft

Cold storage, the default for decades, limits how long an organ can be kept and gives no chance to assess or repair it5. Ex vivo machine perfusion—pumping oxygenated, nutrient-rich fluid through an organ outside the body—was explored from the 1960s, notably by Folkert Belzer in Wisconsin, but entered clinical practice in earnest in the 2010s. Normothermic perfusion, which keeps a liver or lung at body temperature and metabolically active, allows surgeons to test function before implanting and to treat marginal organs that would once have been discarded; hypothermic oxygenated perfusion, developed in the 2010s, appears to reduce injury in livers and kidneys. The technique has changed procurement: organs from donors after circulatory death, long considered unusable, can now be assessed and sometimes rehabilitated. It has also reopened a basic question—what exactly makes an organ viable—that cold storage had allowed surgeons to ignore.

Tolerance: The Unfinished Goal

The dream that runs through the whole history is operational tolerance: a state in which a recipient accepts a graft without lifelong drugs6. Medawar's acquired tolerance showed it was biologically possible in principle6. Clinical attempts have included donor bone-marrow infusion alongside kidney transplantation, pioneered in the 1990s and 2000s by teams in Pittsburgh, Stanford, and elsewhere, and protocols that deliberately mix donor and recipient immune cells. A small number of patients—most famously some kidney recipients in these trials—have been withdrawn from immunosuppression and remain stable, but the approaches are demanding, carry risks of graft-versus-host disease (in which donor immune cells attack the recipient), and have not become standard. The field today is therefore split between refining conventional immunosuppression and pursuing cell-based or gene-based strategies to induce tolerance, and the question of which patients can safely stop drugs remains unanswered.

The Present

Transplant surgery today is a mature specialty organized around organ-specific programmes, national allocation systems, and immunosuppressive regimens that have made one-year graft survival the norm for kidney, liver, and heart recipients. Its live questions descend directly from the history above: how to expand the donor pool without exploiting living donors; how to use machine perfusion to rescue organs once discarded; how to match the right organ to the right patient under scarcity; and whether tolerance can be made reliable enough to free patients from drugs. The field's founding insight—that the surgeon's craft can reconnect an organ but only immunology can keep it—still defines its work.

References

  1. Transplantation (medicine) (introduction, Isograft), Wikipedia
  2. Kidney transplantation (History), Wikipedia
  3. Lung transplantation (History), Wikipedia
  4. Pancreas transplantation (History), Wikipedia
  5. Machine perfusion, Wikipedia
  6. Immune tolerance (introduction, Historical background), Wikipedia

The frameworks of Transplant Surgery

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1902-Present

    Vascular Anastomosis Technique

    How can two blood vessels be joined so blood flows?

    Fly to its tower in Nousfarer

  2. 1945-Present
  3. 1954-Present

    Living Donation

    Can a healthy person safely give an organ to another?

    Fly to its tower in Nousfarer

  4. 1963-Present

    Immunosuppressive drug

    Which drugs can stop the immune system from rejecting an organ?

    Fly to its tower in Nousfarer

  5. 1963-Present

    Organ-Specific Transplant Programmes

    How can each failing organ be replaced by surgery?

    Fly to its tower in Nousfarer

  6. 1964-Present

    Xenotransplantation

    Can animal organs be used to save human lives?

    Fly to its tower in Nousfarer

  7. 1967-Present

    Allocation and Procurement Policy

    Who should get a scarce organ and how should it be obtained?

    Fly to its tower in Nousfarer

  8. 1968-Present

    Brain Death and the Dead Donor Rule

    When is a person dead enough to take their organs?

    Fly to its tower in Nousfarer

  9. 1990-Present

    Operational Tolerance Induction

    Can the immune system be taught to accept one organ?

    Fly to its tower in Nousfarer

  10. 2010-Present

    Machine perfusion

    Can machines keep an organ alive outside the body?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Vascular Anastomosis TechniqueTransplantation Immunology and Histoc…Living DonationImmunosuppressive drugOrgan-Specific Transplant ProgrammesXenotransplantationAllocation and Procurement PolicyBrain Death and the Dead Donor RuleOperational Tolerance InductionMachine perfusion

Beyond the field

Where Transplant Surgery's ideas came from in other fields, and what they led to there: the strongest 12 of 54 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Transplant Surgery is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Transplant Surgery

Related fields

Fields its ideas are linked to

More in Surgery

See where Transplant Surgery sits on the Map of Human Knowledge